CARM · As filed with the SEC

Carisma Therapeutics cash flow statement, by quarter

The statement as Carisma Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

Unaudited Consolidated Statements of Cash Flows · USD thousands

USD thousands	Q3 2025 3 months ended Sep 30, 2025	Q2 2025 3 months ended Jun 30, 2025	Q1 2025 3 months ended Mar 31, 2025	Q4 2024^† 3 months ended Dec 31, 2024
Cash flows from operating activities:
Net income (loss)	—	—	(9,266,000)	—
Adjustment to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	—	—	661,000	—
Stock-based compensation expense	—	—	508,000	—
Reduction in the operating right of use assets	—	—	877,000	—
Amortization of debt discount	—	—	—	0^†
Change in fair value of derivative liability	—	—	—	0^†
Accretion on marketable securities	—	—	—	0^†
Write-off of property and equipment	—	—	—	288^†
Write-off of deferred financing costs	—	—	208,000	—
Gain (loss) on sale of property and equipment	—	—	(113,000)	—
Non-cash interest expense	—	—	19,000	—
Changes in operating assets and liabilities:
Prepaid expenses and other assets	—	—	3,015,000	—
Accounts payable	—	—	1,170,000	—
Accrued expenses	—	—	(2,743,000)	—
Deferred revenue	—	—	(3,729,000)	—
Operating lease liabilities	—	—	(707,000)	—
Other long term liabilities	—	—	33,000	—
Net cash used in operating activities	—	—	(10,067,000)	—
Cash flows from investing activities:
Purchase of marketable securities	—	—	—	0^†
Proceeds from the sale of marketable securities	—	—	—	0^†
Proceeds from the sale of property and equipment	—	—	524	—
Purchases of property and equipment	—	—	0	—
Net cash provided by (used in) investing activities	—	—	524,000	—
Cash flows from financing activities:
Cash, cash equivalents and restricted cash acquired in connection with the reverse recapitalization	—	—	—	0^†
Payment of reverse recapitalization finance costs	—	—	—	0^†
Proceeds from the issuance of common stock in pre-closing financing	—	—	—	0^†
Payment of principal related to finance lease liabilities	—	—	(304,000)	—
Proceeds from failed sale-leaseback arrangement	—	—	0	—
Payment of finance liability from failed sale-leaseback arrangements	—	—	(327,000)	—
Payment of deferred financing costs	—	—	—	0^†
Proceeds from the exercise of stock options	—	—	5,000	—
Sale of common stock under Open Market Sale Agreement, net of issuance costs	—	—	0	—
Net cash (used in) provided by financing activities	—	—	(626,000)	—
Net decrease in cash, cash equivalents and restricted cash	—	—	(10,169,000)	—
Cash, cash equivalents, and restricted cash at beginning of the year	1,999,000	7,740,000	17,909,000	26,881,000
Cash, cash equivalents and restricted cash at end of the period	2,777,000	1,999,000	7,740,000	17,909,000
Supplemental disclosures of cash flow information:
Cash paid for interest	—	—	33,000	—
Supplemental disclosure of non-cash financing and investing activities:
Conversion of convertible preferred stock and non-controlling interests upon Merger	—	—	—	0^†
Conversion of convertible promissory note, accrued interest and derivative liability upon Merger	—	—	—	0^†
Unrealized gain on marketable securities	—	—	—	0^†
Right-of-use assets obtained in exchange for new operating lease liabilities	—	—	836,000	—
Right-of-use assets obtained in exchange for new finance lease liabilities	—	—	0	—
Property and equipment in accounts payable	—	—	0	—

† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.